Moderna stock’s 17% slump was a ‘sell the news’ event, analyst says

Moderna shares tumbled after leaked cancer vaccine trial data showed promising results for its treatment developed with Merck.

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.thestreet.com)